SGMT
Sagimet Biosciences Inc. Series A
10.40$
-6.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
Sagimet Biosciences Inc. Series A (SGMT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -46 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -11 | -10 | -22 | -24 | -24 | -42 | -46 | |
| 0.0 | 0.1 | 0.1 | 0.1 | – | – | – | |
| 3.0 | 0.8 | 1.9 | 1.9 | 5.0 | 5.3 | 6.4 | |
| 3.1 | 0.9 | – | – | – | – | – | |
| 0.6 | 0.1 | -0.1 | 4.2 | -1.0 | -1.0 | -1.1 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | – | -32 | 13 | -62 | 4.6 | |
| -3.4 | – | – | – | – | – | – | |
| 18 | 69 | 9.7 | -0.1 | 86 | 105 | 0.3 | |
| 7.9 | 58 | -12 | -57 | 75 | 0.7 | -41 | |
| -11 | -10 | -22 | -24 | -24 | -42 | -46 |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.